FRAX at 15 Years: How the Fracture Risk Assessment Tool Changed Osteoporosis Care
A comprehensive review examines 15 years of FRAX validation data, showing its strengths in predicting 10-year fracture probability and its known limitations.
Read the original article at Journal of Endocrinological InvestigationKairos™'s Take
Kairos™'s perspective on this story
First released in 2008, the FRAX (Fracture Risk Assessment Tool) has become the most widely used clinical calculator for estimating 10-year fracture probability. A 2023 review published in the Journal of Endocrinological Investigation examined 15 years of validation data from cohorts across four continents. FRAX integrates clinical risk factors — age, sex, BMI, prior fracture, parental hip fracture, glucocorticoid use, smoking, alcohol, rheumatoid arthritis, and secondary osteoporosis — with or without femoral neck BMD to produce a probability score for major osteoporotic and hip fractures.
The validation evidence is substantial. FRAX was developed from meta-analyses of 12 prospective studies covering more than 60,000 individuals and over 250,000 person-years of follow-up. The SCOOP trial demonstrated that FRAX-based screening led to a 28% reduction in hip fractures. Country-specific models now exist for dozens of nations, calibrated to local fracture and mortality epidemiology. However, the review also acknowledged known limitations: FRAX does not account for fall history, dose-response effects of risk factors, or newer bone quality measures like trabecular bone score.
Why This Matters for Midlife Health
FRAX gives clinicians a standardized way to convert clinical information into a quantified risk estimate. For women approaching or in midlife, that estimate can determine whether a DXA scan is ordered, whether treatment is initiated, or whether monitoring continues. But the tool is only as good as the data fed into it. Incomplete or inaccurate risk factor information produces incomplete risk estimates. Knowing your own risk factors — and having them documented — directly affects the quality of your FRAX output.
The Tracking Connection
Every input to FRAX is a data point that can be maintained over time: body weight, fracture history, medication use, smoking status, family history. Kairos™ helps users keep these risk factors organized and accessible. When your provider runs a FRAX calculation, the accuracy of the result depends on the accuracy of the inputs. A longitudinal health record — one that captures changes in weight, new medications, or a parent's fracture history — ensures that risk assessment reflects reality, not recall.
Ready to start tracking?
Kairos™ tracks, scores, and interprets the symptoms of midlife hormonal change — for both women and men.
Get StartedMore from the newsroom
SWAN Study: Bone Loss Accelerates Sharply During the Menopause Transition
The landmark SWAN longitudinal study showed that bone mineral density remains stable in early perimenopause but declines sharply in late perimenopause — about 2% per year — continuing into early postmenopause.
The FREEDOM Trial: Denosumab Reduces Vertebral Fractures by 68% in Postmenopausal Women
The landmark FREEDOM trial published in NEJM showed that denosumab, a monoclonal antibody, significantly reduced vertebral, hip, and nonvertebral fractures in women with osteoporosis over 3 years.
The Treatment Gap in Osteoporosis: Fewer Than 20% of High-Risk Patients Receive Care
A comprehensive review documents the growing osteoporosis treatment gap — with diagnosis rates below 20% and post-fracture treatment rates declining despite effective therapies being available.